DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Targeted enzymatic therapy for coeliac disease
[Data availability]
The coordinates of the experimental celiacase structure determined in this study are retrievable from the Protein Data Bank at www.pdb.org under access code 9QR8. The proteomics datasets are retrievable from Zenodo (https://zenodo.org/records/19456489)., The source data of this paper are collected in the following database record: biostudies:S-SCDT-10_1038-S44321-026-00430-8., Coeliac disease (CD) is an autoimmune enteropathy triggered by proline-rich gluten immunogenic peptides (GIPs), for which no curative therapy exists. We developed celiacase (Clc), a recombinant prolyl endopeptidase engineered from pitcher plant neprosin to enhance expression, stability, and activity. Clc showed maximal activity at gastric pH, synergized with and resisted pepsin, and efficiently cleaved GIPs, including the highly immunogenic 33-mer, outperforming Aspergillus niger prolyl endopeptidase in degrading GIPs from wheat flour and gliadin. At an enzyme-to-gliadin ratio of 1:250, Clc reduced GIP levels by up to 99% in a dynamic human gastrointestinal simulator. Ex vivo, Clc-digested 33-mer fragments failed to elicit cytokine responses in mouse and rat macrophages and duodenal biopsies from CD patients. In vivo, low-dose Clc (1:75-1:380) degraded gliadin and attenuated pathology in gliadin-fed mice, reducing villus atrophy, inflammation, antibody responses, and gluten-induced dysbiosis, while restoring immune-regulatory markers and microbial metabolic pathways. In summary, Clc is a potent, acid-stable glutenase with promise as a therapeutic adjunct or alternative to a gluten-free diet for CD patients., This study was supported in part by funding from public and private bodies, which had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MCIN/AEI/10.13039/501100011033: PDC2022-133344-I00, PID2022-137827OB-I00, PID2025-171123OB-I00 (FXG-R); RYC2020-029773-I, PID2021-128682OA-I00, PID2024-159901OB-I00, CNS2024-154537 (UE); PRE2020-096731 (JSR-L); PRE2022-000841 (HS); CEX2021-001234-M “María de Maeztu” Unit of Excellence Award (FJP-C). “Vicente Varea 2025” Grant (FJP-C)—Celiac Association of Catalonia. PREDOCS-UB Predoctoral Contract University of Barcelona (2022 call) (MG). Agency for Management of University and Research Grants (AGAUR), Government of Catalonia grant 2021SGR00423 (UE; FXG-R). CONEXIÓN TRIGO Network—Higher Scientific Research Council (CSIC)., With funding from the Spanish government through the "Unit of Excellence Maria de Maeztu" accreditation (CEX2021-001234-M)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PDC2022-133344-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-137827OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2024-2027 RYC2020-029773-I
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2021-128682OA-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2024-159901OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2024-2027 CNS2024-154537
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2024-2027 PRE2020-096731
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 CEX2021-001234-M